You are here

Acute Coronary Syndrome

 

Based on clinical guidelines, three therapies are often prescribed together following acute MI: angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs), beta-blockers and statins. But are they equally important?

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase of 21 percent for suffering a heart attack.

Patients who have suffered a previous heart attack remain at increased risk for another myocardial infarction (MI), cardiovascular death or stroke, with no indication of the risk level waning over time. According to new research, the optimal dose of ticagrelor shows consistent benefits in reducing ischemic risk over five-plus years in heart attack patients, while its added risk for major bleeding events abates over time.

Despite proven survival benefits, roughly two-thirds of heart attack patients forego cardiac rehabilitation, according to a report from the Centers for Disease Control and Prevention (CDC).

National organizations, state governments and local communities have attempted to battle out-of-hospital cardiac arrest (OHCA) by supporting public awareness and improving preparedness, most notably through CPR training and use of automated external defibrillators (AEDs). A recent study—published online July 31 in Resuscitation, the journal of the European Resuscitation Council—examined the effectiveness of the Minnesota Heart Safe Communities program.

 

Recent Headlines

Adherence to medications post-MI is below 50%; beta-blockers offer little incremental benefit

Based on clinical guidelines, three therapies are often prescribed together following acute MI: angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs), beta-blockers and statins. But are they equally important?

Researchers confirm link between retinal vein occlusion, heart attack

In a large, retrospective study of the Taiwan population, researchers found individuals with retinal vein occlusion (RVO) demonstrated an adjusted risk increase of 21 percent for suffering a heart attack.

Ticagrelor shows long-term benefit in those with previous MI

Patients who have suffered a previous heart attack remain at increased risk for another myocardial infarction (MI), cardiovascular death or stroke, with no indication of the risk level waning over time. According to new research, the optimal dose of ticagrelor shows consistent benefits in reducing ischemic risk over five-plus years in heart attack patients, while its added risk for major bleeding events abates over time.

CDC: 2 of 3 heart attack patients spurn rehab

Despite proven survival benefits, roughly two-thirds of heart attack patients forego cardiac rehabilitation, according to a report from the Centers for Disease Control and Prevention (CDC).

Does public awareness of CPR, AEDs reduce response time to cardiac arrest?

National organizations, state governments and local communities have attempted to battle out-of-hospital cardiac arrest (OHCA) by supporting public awareness and improving preparedness, most notably through CPR training and use of automated external defibrillators (AEDs). A recent study—published online July 31 in Resuscitation, the journal of the European Resuscitation Council—examined the effectiveness of the Minnesota Heart Safe Communities program.

Study confirms effectiveness of new-generation heart stents in women

New-generation drug-eluting stents (DES) demonstrate long-term safety in women with acute myocardial ischemia (MI), with increased benefits for more severe cases of acute coronary syndrome (ACS), according to a new study.

Local gene therapy improves myocardial blood flow in refractory angina patients

For the first time, researchers have employed local gene therapy to boost myocardial blood flow in areas that have impaired perfusion reserves. They have also determined that elevated plasma Lp(a) can serve as a biomarker to identify those individuals with refractory angina (RA) who can benefit from the experimental therapy, gene transfer of VEGF-DΔNΔC.

Adults with acute coronary syndrome in registry differ from those in clinical trial

A registry analysis found that approximately one-third of patients who currently have acute coronary syndrome would have qualified for the IMPROVE-IT trial, which enrolled patients between 2005 and 2010.